非小细胞肺癌（NSCLC）的治疗。
Treatment of non-small cell lung cancer (NSCLC).
作者信息
Zarogoulidis Konstantinos, Zarogoulidis Paul, Darwiche Kaid, Boutsikou Efimia, Machairiotis Nikolaos, Tsakiridis Kosmas, Katsikogiannis Nikolaos, Kougioumtzi Ioanna, Karapantzos Ilias, Huang Haidong, Spyratos Dionysios
机构信息
Pulmonary Department-Oncology Unit, "G. Papanikolaou" General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece;
出版信息
J Thorac Dis. 2013 Sep;5 Suppl 4(Suppl 4):S389-96. doi: 10.3978/j.issn.2072-1439.2013.07.10.
Abstract
Radical surgery is the standard of care for fit stage I non-small cell lung cancer (NSCLC) patients. Adjuvant treatment should be offered only as part of an investigation trial. Stage II and IIIA adjuvant cisplatin-based chemotherapy remains the gold standard for completely resected NSCLC tumors. Additionally radiotherapy should be offered in patients with N2 lymph nodes. In advanced stage IIIB/IV or inoperable NSCLC pts, a multidisciplinary treatment should be offered consisted of 4 cycles of cisplatin-based chemotherapy plus a 3(rd) generation cytotoxic agent or a cytostatic (anti-EGFR, anti-VEGFR) drug.
摘要
根治性手术是适合的Ⅰ期非小细胞肺癌（NSCLC）患者的标准治疗方法。辅助治疗仅应作为研究试验的一部分提供。Ⅱ期和ⅢA期以顺铂为基础的辅助化疗仍然是完全切除的NSCLC肿瘤的金标准。此外，N2淋巴结阳性患者应接受放疗。对于晚期ⅢB/Ⅳ期或无法手术的NSCLC患者，应提供多学科治疗，包括4个周期的以顺铂为基础的化疗加第三代细胞毒性药物或细胞生长抑制剂（抗EGFR、抗VEGFR）药物。
相似文献
1
Treatment of non-small cell lung cancer (NSCLC).
J Thorac Dis. 2013 Sep;5 Suppl 4(Suppl 4):S389-96. doi: 10.3978/j.issn.2072-1439.2013.07.10.
2
Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
Cancer Prev Control. 1997 Dec;1(5):366-78.
3
Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study.
Lung Cancer. 2020 Dec;150:164-171. doi: 10.1016/j.lungcan.2020.09.027. Epub 2020 Oct 8.
4
Report of phase II trial of concurrent chemoradiotherapy with radical thoracic irradiation (60 Gy), infusional fluorouracil, bolus cisplatin and etoposide for clinical stage IIIB and bulky IIIA non-small cell lung cancer.
Int J Radiat Oncol Biol Phys. 1993 Jun 15;26(3):469-78. doi: 10.1016/0360-3016(93)90965-x.
5
Induction chemotherapy followed by concurrent chemotherapy and definitive high-dose radiotherapy for patients with locally advanced non-small-cell lung cancer (stages IIIa/IIIb): a pilot phase I/II trial.
Ann Oncol. 2002 Mar;13(3):403-11. doi: 10.1093/annonc/mdf050.
6
Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.
Lancet Respir Med. 2018 Nov;6(11):863-873. doi: 10.1016/S2213-2600(18)30277-7. Epub 2018 Aug 24.
7
Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
Cancer. 1996 Jun 1;77(11):2393-9. doi: 10.1002/(SICI)1097-0142(19960601)77:11<2393::AID-CNCR31>3.0.CO;2-Q.
8
Docetaxel (Taxotere) in the neo-adjuvant setting in non-small-cell lung cancer.
Ann Oncol. 1999;10 Suppl 5:S69-72. doi: 10.1093/annonc/10.suppl_5.s69.
9
A phase II randomized trial of adjuvant chemotherapy with S-1 versus S-1 plus cisplatin for completely resected pathological stage II/IIIA non-small cell lung cancer.
Lung Cancer. 2018 Oct;124:255-259. doi: 10.1016/j.lungcan.2018.08.015. Epub 2018 Aug 19.
10
Randomized phase II trial of adjuvant chemotherapy with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: TORG 0503.
Lung Cancer. 2020 Mar;141:32-36. doi: 10.1016/j.lungcan.2019.11.009. Epub 2019 Nov 29.
引用本文的文献
1
Predicting pathological staging of non-small cell lung cancer using a multi-task radiomics model integrating intratumoral and peritumoral features.
Oncol Lett. 2025 Jul 7;30(3):431. doi: 10.3892/ol.2025.15177. eCollection 2025 Sep.
2
Assessing the Data Quality Dimensions of Surgical Oncology Cohorts in the Research Program.
JCO Clin Cancer Inform. 2025 Jul;9:e2500078. doi: 10.1200/CCI-25-00078. Epub 2025 Jul 8.
3
Pyrazole in drug development: a medicinal-chemistry based analysis of USFDA-approved drugs in last decade.
Mol Divers. 2025 Jun 23. doi: 10.1007/s11030-025-11260-0.
4
Prediction of PD-L1 tumor positive score in lung squamous cell carcinoma with H&E staining images and deep learning.
Front Artif Intell. 2024 Dec 20;7:1452563. doi: 10.3389/frai.2024.1452563. eCollection 2024.
5
Precision Nanomedicine: Lapatinib-Loaded Chitosan-Gold Nanoparticles Targeting LINC01615 for Lung Cancer Therapy.
AAPS J. 2024 Nov 19;27(1):4. doi: 10.1208/s12248-024-00990-y.
6
Mitochondrial VDAC1 Silencing in Urethane-Induced Lung Cancer Inhibits Tumor Growth and Alters Cancer Oncogenic Properties.
Cancers (Basel). 2024 Aug 26;16(17):2970. doi: 10.3390/cancers16172970.
7
Impact of interplay effects on spot scanning proton therapy with motion mitigation techniques for lung cancer: SFUD versus robustly optimized IMPT plans utilizing a four-dimensional dynamic dose simulation tool.
Radiat Oncol. 2024 Sep 9;19(1):117. doi: 10.1186/s13014-024-02518-2.
8
Oral inhalation of dacomitinib nanocarriers as a therapeutic strategy for non-small cell lung cancer.
Nanomedicine (Lond). 2024;19(18-20):1601-1613. doi: 10.1080/17435889.2024.2370225. Epub 2024 Jul 29.
9
Polydatin, a potential NOX5 agonist, synergistically enhances antitumor activity of cisplatin by stimulating oxidative stress in non‑small cell lung cancer.
Int J Oncol. 2024 Aug;65(2). doi: 10.3892/ijo.2024.5665. Epub 2024 Jun 14.
10
Cigarette smoke sustains immunosuppressive microenvironment inducing M2 macrophage polarization and viability in lung cancer settings.
PLoS One. 2024 May 22;19(5):e0303875. doi: 10.1371/journal.pone.0303875. eCollection 2024.
本文引用的文献
1
Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer.
Onco Targets Ther. 2013;6:125-34. doi: 10.2147/OTT.S42245. Epub 2013 Mar 1.
2
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26.
3
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
J Clin Oncol. 2011 Jul 20;29(21):2866-74. doi: 10.1200/JCO.2010.33.4235. Epub 2011 Jun 13.
4
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial.
Lancet. 2011 May 28;377(9780):1846-54. doi: 10.1016/S0140-6736(11)60545-X.
5
The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer.
J Thorac Oncol. 2009 Jul;4(7):792-801. doi: 10.1097/JTO.0b013e3181a7716e.
6
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.
J Clin Oncol. 2009 Mar 10;27(8):1227-34. doi: 10.1200/JCO.2007.14.5466. Epub 2009 Feb 2.
7
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
J Clin Oncol. 2008 Jul 20;26(21):3552-9. doi: 10.1200/JCO.2007.13.9030. Epub 2008 May 27.
8
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
J Clin Oncol. 2008 Jul 20;26(21):3543-51. doi: 10.1200/JCO.2007.15.0375. Epub 2008 May 27.
9
Cancer statistics, 2008.
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. doi: 10.3322/CA.2007.0010. Epub 2008 Feb 20.
10
Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.
J Clin Oncol. 2008 Jan 1;26(1):60-5. doi: 10.1200/JCO.2007.13.1144.
Zotero 插件